



Article

A Dieckmann cyclization route to piperazine-2,5-diones

Claude Larrivee Aboussafy, and Derrick L. J. Clive

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/jo3007144 • Publication Date (Web): 07 May 2012

Downloaded from http://pubs.acs.org on May 14, 2012

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



A Dieckmann cyclization route to piperazine-2,5-diones

Claude Larrivée Aboussafy and Derrick L. J. Clive*

Chemistry Department, University of Alberta, Edmonton, Alberta T6G 2G2, Canada

*E-mail: derrick.clive@ualberta.ca

$$\begin{array}{c} R^3 \\ R^1 \\ N \\ CO_2Ph \\ N \\ R^2 \\ R^1, R^2 = \text{alkyl groups;} \\ R^3 = \text{PhCO, PmbCO, MeCO, CN, CO}_2Me, P(O)(OEt)_2 \end{array}$$

ABSTRACT

Piperazine-2,5-diones are formed by Dieckmann cyclization (NaH, THF) of substructures of the type $\mathbf{CH_2}$ -N(R)C(O)CH₂N(R')CO₂Ph in which the terminal methylene ($\mathbf{CH_2}$) that is adjacent to nitrogen closes onto the carbonyl group of the phenyl carbamate unit at the other end of the chain. R and R' are alkyl groups and the terminal methylene is activated by a ketone carbonyl, a nitrile, an ester, or a phosphoryl group. The starting materials are assembled by standard acylation and oxidation processes, starting from a β -(alkylamino)alcohol, an (alkylamino)acetonitrile, an (alkylamino) ester or an (alkylamino)methyl phosphonate.

INTRODUCTION

During synthetic studies carried out in this laboratory and directed towards the synthesis of the antitumor antibiotic MPC1001 (1), the lactam carbamate 2 was treated with NaH to produce the piperazinedione 3 (eq 1). In this process, the piperazine-2,5-dione substructure of 3 is being

constructed by the potentially general sequence $4\rightarrow 5$ (eq 2) which resembles the classical Dieckmann cyclization. Surprisingly, the simple disconnection represented by the conversion of 4 into 5 has not been used before, apart from the example of eq 1.² In view of the importance of piperazine-2,5-diones,³ especially for pharmaceutical products,⁴ we decided to establish if any special features inherent in structure 2, especially the restraint of the ketone carbonyl group into

a ring, was a requirement for effective cyclization, and we now report that the process defined by eq 2 represents a general route to piperazine-2,5-diones. It allows the preparation of such compounds bearing a variety of different substituents.⁵

RESULTS AND DISCUSSION

The starting carbamates related to generic structure **4** were easily prepared, often along the lines summarized in Scheme 1 for a particular example, and Table 1 lists the carbamates we have made in this way or by equally straightforward routes (which are described in the experimental section).

SCHEME 1. Preparation of amide carbamate 6d

TABLE 1. Preparation of substrates for cyclization

^aCorrected for recovered **13b**.

All of the starting amino alcohols (Table 1, first column) are known compounds; those of entries 1-5, 9 and 10 were made by the epoxide route (cf Scheme 1). Although compound **10a** (entry 6) could also be prepared in this way, reductive amination (NaBH₃CN) of *p*-methoxybenzaldehyde gave a better yield. The cyano amine **11a** was available in one step from ClCH₂CN and BnNH₂, and the amino phosphonate **14a** was made from (EtO)₂P(O)H and 1,3,5-tribenzyl-1,3,5-triazinane.⁶

Each amino alcohol was acylated on nitrogen using one of the acid chlorides 7, 15 or 16, which were made by N-acylation (PhOCOCl, or p-O₂NC₆H₄OCOCl) of the appropriate amino acid, followed by treatment with (COCl)₂. The resulting hydroxy carbamates were then oxidized (cf $6c\rightarrow6d$) with PCC or the Dess-Martin reagent.

$$\begin{array}{ccc} \text{CO}_2\text{C}_6\text{H}_4\text{NO}_2\text{-}\rho & \text{CIOC} \\ & \text{N}_{\cdot}\text{Me} & \text{CIOC} \\ & & \text{15} & \text{16} \end{array}$$

When carbamate **6d** was heated with NaH (2.05 equiv) in refluxing THF (0.02 M in **6d**) for 15 min, it was converted into the piperazinedione **6g** in 67% yield (92% after correction for recovered **6d**). These conditions represent the best results from a brief optimization study in which we varied, in an empirical manner, the reaction temperature (room temperature and 70 °C), the concentration of the starting carbamate (0.2 M and 0.02 M), the solvent (THF, DMF, DMSO), and the nature of the base (NaH, *t*-BuOK, DBU, LDA, KHMDS, LiHMDS). The

related carbamate **6f** gave **6g** in much lower yield under the same conditions. A similar comparison was made between **9c** and **9e**, and once again the phenyl carbamate was far superior. We did not establish the basis of this result, but speculate that the better leaving group facilitates the incursion of intermolecular side reactions. Cyclization of **6d** did not occur with CF₃CO₂H (CH₂Cl₂) or TsOH (CDCl₃). In two cases, (Table 2, entries 8 and 11) the cyclization was done in the presence of a small amount of *t*-BuOH (0.2 equiv). With this change, the experiment of entry 8 gave a higher yield, and that of entry 11 proceeded more rapidly. This modification was tried because these two examples were abnormally slow under the usual conditions.

TABLE 2. Cyclization to piperazine-2,5-diones^a

^aUnless otherwise indicated, reactions were done using the following conditions: NaH (2.05 equiv), 0.02 M in substrate, THF, 70 °C, 15 min. ^bCorrected for recovered starting material. ^cReaction time = 24 h, trace *t*-BuOH added. ^dReaction time = 2.5 h. ^eReaction time = 30 min. ^fReaction time = 4.5 h, trace *t*-BuOH added. ^gThe material contained a minor byproduct (see text).

The reaction accommodates different alkyl groups on nitrogen (methyl, benzyl, p-methoxybenzyl). As indicated in Table 2, we have also investigated a limited number of activating groups adjacent to the carbon [C(6) in 4] that must be deprotonated to initiate the ring closure. PhCO and p-MeOC₆H₄CO are satisfactory (entries 1-5, 9, 10) as are MeCO (entry 6) and CO₂Me (entry 8). Use of a nitrile for activation is also successful (entry 7) as is a diethoxyphosphoryl group (entry 11).

In the case of entry 9, two chromatogaphically inseparable products (ca 89:11) were formed and the NMR spectra suggest that they are the expected *cis* and *trans* isomers, although we were unable to identify which was which. We noted that in the ¹H and ¹³C NMR spectra of the material, the minor signals were very similar to those corresponding to the major isomer, but slightly displaced.

The phosphonate **14c** contained a minor byproduct that could not be separated and, when we treated the material with *p*-methoxybenzaldehyde and NaH, the two olefins **14d** (50%) and **14d'** (15%) (Figure 1) were isolated, suggesting that the minor component of the starting phosphonate **14c** was a positional isomer with the phosphoryl group adjacent to the *N*-methyl. Very few phosphonates of piperazine-2,5-diones have been reported.⁷ The stereochemistry of

14d and **14d'** was evident from TROESY (Figure 1) and HMBC NMR experiments, (see Supporting Information), but we did not establish the origin of the minor phosphonate that gives **14d'**.

Figure 1. Structures and TROESY correlations for 14d and 14d'.

In the case of **6d** a minor byproduct was sometimes obtained. This material had structure **6h**. When **6d** was treated with NaH in THF under an atmosphere of O₂, the same imidazolidinedione **6h** was the exclusive product (56% yield) but when **6g** was subjected to the same conditions we did not detect **6h**.

Piperazinediones **10d**, **11c**, and **12c** are crystalline, and single crystal X-ray analysis served to confirm the structures and indicate the shape of the heterocyclic ring (see Supporting Information for ORTEP diagrams). Both compounds **10d** and **12c** have a shallow boat conformation with their respective carbonyl substituents (MeCO and CO₂Me) axial, while **11c** has an almost planar heterocyclic ring.

EXPERIMENTAL SECTION

General Procedures. Solvents used for chromatography were distilled before use. Commercial thin layer chromatography (TLC) plates (silica gel, Merck 60F–254) were used. Silica gel for flash chromatography was Merck type 60 (230-400 mesh). Dry solvents were prepared under an inert atmosphere and transferred by syringe. Molecular sieves (3 Å) were stored at 150 °C for 5 h, and then cooled in a desiccator under N₂, before use. The symbols s, d, t, q used for ¹³C NMR spectra indicate zero, one, two, or three attached hydrogens, respectively, the assignments being made by APT spectra. Solutions were evaporated under water pump vacuum and the residue was kept under oil pump vacuum. High resolution mass spectra were obtained with an aoTOF mass analyzer fitted with an electrospray source. NMR spectra of many compounds were run both at room temperature and at a higher temperature (usually at 100 °C) in order to verify the presence of rotamers. Samples for X-ray analysis were crystallized as follows: A portion of the sample was dissolved in the minimum amount of EtOAc at room temperature and the solution was transferred to a shortened (ca 4 cm) NMR tube. This was placed inside a sample vial containing hexane and the vial was closed. After several days crystals suitable for X-ray analysis had grown.

Phenyl N-{[Benzyl(2-hydroxy-2-phenylethyl)carbamoyl]methyl}-N-methylcarbamate (6c). NaHCO₃ (185 mg, 2.20 mmol) was added to a stirred and cooled (0 °C) solution of 6b⁹ (200 mg, 0.881 mmol) in dioxane (3 mL) and water (3 mL). Acid chloride 7¹ (250 mg, 1.10 mmol) in dry THF (1 mL) was added dropwise over 15 min. The cooling bath was left in place, but not recharged, and stirring was continued overnight. The THF and dioxane were evaporated and the aqueous solution was extracted with CH₂Cl₂. The combined organic extracts were dried

(Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 12 cm), using 30% to 50% EtOAc in hexanes, gave **6c** (306 mg, 83%) as a white foam: FTIR (CHCl₃, cast) 3422, 3063, 3030, 2935, 1723, 1650, 1495, 1475, 1453, 1398, 1205 cm⁻¹; ¹H NMR (DMSO- d_6 , 400 MHz) δ 2.82-3.02 (four s, 3 H in all), 3.14-3.31 (m, 1 H), 3.43-3.56 (m, 1 H), 4.14-4.24 (m, 1.3 H), 4.40-4.53 (m, 1.7 H), 4.60-4.67 (m, 0.3 H), 4.78-4.87 (m, 1.7 H), 5.50-5.51 (m, 0.3 H), 5.75-5.77 (m, 0.7 H), 7.00-7.40 (m, 15 H); ¹³C NMR (DMSO- d_6 , 125 MHz) δ 35.7 (q), 35.8 (q), 36.1 (q), 36.2 (q), 48.2 (t), 48.4 (t), 50.4 (t), 50.6 (t),50.7 (t), 50.8 (t), 53.4 (t), 53.9 (t), 70.3 (d), 70.8 (d), 121.6 (d), 121.7 (d), 124.9-129.2 (numerous d), 137.0 (s), 137.7 (s), 143.1 (s), 143.1 (s), 143.4 (s), 151.2 (s), 151.3 (s), 151.4 (s), 154.6 (s), 154.9 (s), 168.0 (s), 168.3 (s), 168.5 (s), 168.7 (s); exact mass (electrospray) m/z calcd for $C_{25}H_{26}N_2NaO_4$ (M + Na) 441.1785, found, 441.1787.

Phenyl *N*-{[Benzyl(2-oxo-2-phenylethyl)carbamoyl]methyl}-*N*-methylcarbamate (6d). PCC (435 mg, 2.02 mmol) was added to a stirred and cooled (0 °C) mixture of 6c (282 mg, 0.674 mmol), AcONa (55 mg, 0.674 mmol) and powdered 3 Å molecular sieves (337 mg, 0.5 g/mmol of 6c) in dry CH₂Cl₂ (10.8 mL). The mixture was stirred at 0 °C for 15 min, the ice bath was removed and stirring was continued for 30 min. The mixture was filtered through a pad of Celite (3.5 x 3.5 cm) and the pad was rinsed with CH₂Cl₂. Flash chromatography silica gel (6.0 g) was added to the filtrate and the solvent was evaporated at room temperature. The dry residue was poured onto the top of a chromatography column made up with silica gel (2 x 16 cm) and hexanes. The column was developed using 40% to 50% EtOAc in hexanes to give 6d (264 mg, 94%) as a white foam: FTIR (CHCl₃, cast) 3063, 3029, 2930, 1724, 1699, 1666, 1472, 1450, 1204 cm⁻¹; ¹H NMR (DMSO- d_6 , 400 MHz) δ 2.89-3.03 (m, 3 H), 4.09-4.19 (two s, 1 H), 4.30-4.40 (two s, 1 H), 4.55-4.56 (m, 1 H), 4.66-4.67 (m, 1 H), 4.82-4.86 (m, 1 H), 5.01-5.02 (m, 1 H), 7.02-7.07 (m, 2 H), 7.18-7.39 (m, 8 H), 7.51-7.55 (m, 2 H), 7.62-7.70 (m, 1 H), 7.95-7.98 (m,

2 H); 13 C NMR (DMSO- d_6 , 125 MHz) δ 35.5 (q), 35.7 (q), 36.1 (q), 36.2 (q), 50.0 (t), 50.1 (t), 50.3 (t), 50.4 (t), 50.6 (t), 50.8 (t), 53.0 (t), 53.2 (t), 53.3 (t), 121.6 (d), 121.7 (d), 125.0 (d), 125.1 (d), 125.1 (d), 126.8-129.2 (numerous d), 129.1 (d), 129.2 (d), 133.5 (s), 133.8 (s), 134.7 (s), 134.9 (s), 136.9 (s), 137.5 (s), 137.5 (s), 151.2 (s), 151.3 (s), 154.5 (s), 154.6 (s), 154.8 (s), 168.2 (s), 168.6 (s), 168.7 (s), 169.1 (s), 193.9 (s), 194.7 (s); exact mass (electrospray) m/z calcd for $C_{25}H_{24}N_2NaO_4$ (M + Na) 439.1628, found, 439.1630.

3-Benzoyl-4-benzyl-1-methylpiperazine-2,5-dione (6g). NaH (60% w/w dispersion in mineral oil, 20 mg, 0.492 mmol) was added in one portion to a stirred solution of 6d (100 mg, 0.240 mmol) in dry THF (12 mL). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 15 min. The mixture was cooled (ice bath) and pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 10 cm), using 20% to 40% EtOAc in hexanes, gave 6g [47 mg, 67% or 92% after correction for recovered **6d** (36 mg)] as a white foam: FTIR (CHCl₃, cast) 3064, 3029, 3008, 2930, 1678, 1596, 1580, 1496, 1466, 1450, 1227 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 2.92 (s, 3 H), 3.92 (d, J = 17.0 Hz, 1 H), 3.96 (d, J = 14.0 Hz, 1 H), 4.36 (d, J = 17.0 Hz, 1 H), 5.07 (d, J = 14.0 Hz, 1 H), 5.53 (s, 1 H), 7.13-7.17 (m, 3 H), 7.21-7.26 (m, 2 H), 7.43-7.49 (m, 2 H), 7.62 (apparent tt, J =1.5, 7.5 Hz, 1 H), 8.00-8.03 (m, 2 H); 13 C NMR (DMSO- d_6 , 125 MHz) δ 34.1 (g), 48.9 (t), 52.6 (t), 65.1 (d), 128.5 (d), 128.9 (d), 129.0 (d), 129.2 (d), 129.9 (d), 134.1 (s), 134.7 (s), 134.7 (d), 160.7 (s), 166.1 (s), 192.6 (s); exact mass (electrospray) m/z calcd for $C_{19}H_{18}N_2NaO_3$ (M + Na) 345.1210, found, 345.1209.

3-Benzoyl-4-benzyl-1-methylpiperazine-2,5-dione (6g). NaH (60% w/w dispersion in mineral oil, 5.3 mg, 0.133 mmol) was added in one portion to a stirred solution of **6f** (30 mg,

0.0650 mmol) in dry THF (3.3 mL). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 30 min. The mixture was cooled (ice bath) and pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (1 x 10 cm), using 20% to 40% EtOAc in hexanes, gave **6g** [5.2 mg, 25% or 33% after correction for recovered **6f** (24.4 mg)] as a white foam.

3-Benzoyl-1,4-dimethylpiperazine-2,5-dione (8d). NaH (60% w/w dispersion in mineral oil, 5 mg, 0.126 mmol) was added in one portion to a stirred solution of **8c** (22 mg, 0.0622 mmol) in dry THF (3.2 mL). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 15 min. The mixture was cooled (ice bath) and pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (1 x 10 cm), using 60% to 70% EtOAc in hexanes, gave **8d**¹⁰ [8.8 mg, 58% or 85% after correction for recovered **8c** (6.8 mg)] as a white solid: mp 114-115 °C, FTIR (CHCl₃, cast) 3064, 2930, 1674 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 2.88 (s, 3 H), 2.93 (s, 3 H), 3.84 (d, J = 17.5 Hz, 1 H), 4.24 (d, J = 17.5 Hz, 1 H), 5.61 (s, 1 H), 7.54 (t, J = 7.5 Hz, 2 H), 7.66 (apparent tt, J = 1.5, 7.5 Hz, 1 H), 8.26-8.28 (m, 2 H); ¹³C NMR (DMSO-d₆, 125 MHz) δ 33.1 (q), 34.0 (q), 52.2 (t), 68.6 (d), 128.9 (d), 130.2 (d), 134.0 (s), 134.8 (d), 160.5 (s), 166.2 (s), 191.8 (s); exact mass (electrospray) m/z calcd for C₁₃H₁₅N₂O₃ (M + H) 247.1077, found, 247.1077.

3-Benzoyl-4-[(4-methoxyphenyl)methyl]-1-methylpiperazine-2,5-dione (9h). NaH (60% w/w dispersion in mineral oil, 6 mg, 0.138 mmol) was added in one portion to a stirred solution of **9c** (30 mg, 0.0671 mmol) in dry THF (3.4 mL). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 15 min. The mixture was cooled (ice

bath) and pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (1 x 10 cm), using 40% EtOAc in hexanes, gave **9h** [18.5 mg, 78% or 85% after correction for recovered **9c** (2.4 mg)] as a white foam: FTIR (neat film) 3065, 2934, 2837, 1676, 1513, 1249 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 2.92 (s, 3 H), 3.73 (s, 3 H), 3.91 (d, J = 17.5 Hz, 1 H), 4.07 (d, J = 14.5 Hz, 1 H), 4.36 (d, J = 17.5 Hz, 1 H), 4.88 (d, J = 14.5 Hz, 1 H), 5.52 (s, 1 H), 6.71-6.73 (m, part of AA'BB' spin system, 2 H), 7.03-7.05 (m, part of AA'BB' spin system, 2 H), 7.45 (t, J = 7.5 Hz, 2 H), 7.60 (t, J = 7.5 Hz, 1 H), 7.99-8.01 (m, 2 H); ¹³C NMR (CDCl₃, 125 MHz) δ 33.9 (q), 48.2 (t), 52.5 (t), 55.3 (q), 64.7 (d), 114.3 (d), 126.4 (s), 128.7 (d), 129.8 (d), 130.7 (d), 134.1 (s), 134.5 (d), 159.7 (s), 160.8 (s), 165.9 (s), 192.7 (s); exact mass (electrospray) m/z calcd for $C_{20}H_{20}N_2NaO_4$ (M + Na) 375.1315, found, 375.1309.

3-Acetyl-4-[(4-Methoxyphenyl)methyl]-1-methylpiperazine-2,5-dione (10d). NaH (60% w/w dispersion in mineral oil, 31 mg, 0.767 mmol) was added in one portion to a stirred solution of **10c** (144 mg, 0.374 mmol) in dry THF (18 mL). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 15 min. The mixture was cooled (ice bath) and pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 10 cm), using 40% to 50% EtOAc in hexanes, gave **10d** [68.4 mg, 63% or 70% after correction for recovered **10c** (14.5 mg)] as pale yellow crystals: mp 112-114 °C, FTIR (CHCl₃, cast) 3007, 2935, 2838, 1732, 1674, 1514, 1464, 1248, 1176 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 2.17 (s, 3 H), 2.93 (s, 3 H), 3.79 (s, 3 H), 3.84 (d, J = 17.5 Hz, 1 H), 4.07 (d, J = 14.5 Hz, 1 H), 4.12 (d, J = 17.5 Hz, 1 H), 4.64 (s, 1 H), 4.85 (d, J = 14.5 Hz, 1 H), 6.83-6.85 (m part of AA'BB' spin system, 2 H), 7.09-7.11 (m part of AA'BB' spin system, 2 H); ¹³C

NMR (DMSO- d_6 , 125 MHz) δ 28.0 (q), 33.9 (q), 48.1 (t), 52.1 (t), 55.3 (q), 69.5 (d), 114.4 (d), 126.3 (s), 130.6 (d), 159.8 (s), 160.4 (s), 164.8 (s), 200.4 (s); exact mass (electrospray) m/z calcd for $C_{15}H_{18}N_2NaO_4$ (M + Na) 313.1159, found, 313.1158. Crystals for X-ray analysis were grown from EtOAc-hexanes, as described in the General Procedures section.

Phenvl *N*-{[Benzyl(cyanoethyl)carbamoyl]methyl}-*N*-methylcarbamate (11b).NaHCO₃ (480 mg, 5.73 mmol) was added to a stirred and cooled (0 °C) solution of 11a¹¹ (335) mg, 2.29 mmol) in dioxane (7 mL) and water (7 mL). Acid chloride 7¹ (651 mg, 2.86 mmol) in dry THF (2.5 mL) was added dropwise over 15 min. The cooling bath was left in place, but not recharged, and stirring was continued overnight. The THF and dioxane were evaporated and the aqueous solution was extracted with CH₂Cl₂. The combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 12 cm), using 40% to 60% EtOAc in hexanes, gave 11b (689 mg, 89%) as a white foam: FTIR (CHCl₃, cast) 3064, 3031, 2941, 1724, 1675, 1496, 1432, 1204 cm⁻¹; ¹H NMR (DMSO-d₆, 500 MHz) δ 2.93-3.08 (two s, 3 H), 4.30-4.48 (m, 3.6 H), 4.59-4.70 (m, 2.4 H), 7.02-7.40 (m, 10 H); ¹³C NMR (DMSO- d_6 , 125 MHz) δ 34.7 (t), 34.9 (t), 35.3 (t), 35.7 (t), 35.9 (q), 36.2 (q), 50.5 (t), 50.6 (t), 50.8 (t), 116.3 (s), 116.5 (d), 121.6 (d), 121.7 (d), 125.2 (d), 125.2 (d), 126.7 (d), 126.9 (d), 127.5 (d), 127.7 (d), 127.7 (d), 128.4 (d), 128.5 (d), 128.7 (d), 128.8 (d), 129.2 (d), 129.3 (d), 135.7 (d), 136.2 (d), 151.1 (s), 151.1 (s), 154.4 (s), 154.6 (s), 168.7 (s), 169.2 (s); exact mass (electrospray) m/z calcd for C₁₉H₁₉KN₃O₃ (M + K) 376.1058, found, 376.1058.

1-Benzyl-4-methyl-3,6-dioxopiperazine-2-carbonitrile (11c). NaH (60% w/w dispersion in mineral oil, 23 mg, 0.565 mmol) was added in one portion to a stirred solution of **11b** (93 mg, 0.276 mmol) in dry THF (12 mL). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 15 min. The mixture was cooled (ice bath) and

pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 8 cm), using 40% to 70% EtOAc in hexanes, gave **11c** [28.8 mg, 43% or 54% after correction for recovered **11b** (19.3 mg)] as pale pink crystals: mp 147-149 °C, FTIR (CHCl₃, cast) 3018, 2932, 1689, 1452, 1266 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 3.04 (s, 3 H), 4.02 (d, J = 18.0 Hz, 1 H), 4.08 (d, J = 14.5 Hz, 1 H), 4.28 (d, J = 18.0 Hz, 1 H), 4.67 (s, 1 H), 5.40 (d, J = 14.5 Hz, 1 H), 7.28-7.39 (m, 5 H); ¹³C NMR (CDCl₃, 125 MHz) δ 34.3 (q), 48.1 (t), 49.9 (d), 51.5 (t), 113.1 (s), 128.9 (d), 129.1 (d), 129.4 (d), 133.0 (s), 156.9 (s), 162.9 (s); exact mass (electrospray) m/z calcd for C₁₃H₁₃N₃NaO₂ (M + Na) 266.0900, found, 266.0899. Crystals for X-ray analysis were grown from EtOAc-hexanes, as described in the General Procedures section.

Methyl 2-{*N*-Methyl-2-|methyl(phenoxycarbonyl)amino|acetamido}acetate (12b). NaHCO₃ (700 mg, 8.37 mmol) was added to a stirred and cooled (0 °C) solution of methyl 2-(methylamino)acetate hydrochloride¹² (260 mg, 1.86 mmol) in dioxane (6 mL) and water (6 mL). Acid chloride 7^1 (530 mg, 2.33 mmol) in dry THF (2 mL) was added dropwise over 15 min. The cooling bath was left in place, but not recharged, and stirring was continued overnight. The THF and dioxane were evaporated and the aqueous solution was extracted with CH₂Cl₂. The combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 12 cm), using 50% to 100% EtOAc in hexanes, gave 12b (477 mg, 87%) as a white foam: FTIR (CH₂Cl₂, cast) 2953, 1726, 1667, 1480, 1397, 1206, 1118 cm⁻¹; ¹H NMR (DMSO- d_6 , 400 MHz) δ 2.84-2.87 (m, 2.6 H), 2.99-3.02 (m, 3.4 H), 3.61-3.69 (four s, 3 H), 4.09-4.13 (m, 1.6 H), 4.21-4.25 (m, 1.6 H), 4.35 (s, 0.8 H), 7.01-7.03 (m, 1.15 H), 7.09-7.11 (m, 0.85 H), 7.16-7.23 (m, 1 H), 7.33-7.38 (m, 2 H); ¹³C NMR (DMSO- d_6 , 125 MHz) δ 34.4 (q), 34.5 (q), 35.0 (q), 35.0 (q), 35.6 (q), 36.0 (q), 49.0 (t), 49.2 (t), 49.7 (t), 50.2 (t), 50.4 (t), 51.7 (q),

52.0 (q), 121.6 (d), 121.8 (d), 125.0 (d), 125.1 (d), 129.1 (d), 129.2 (d), 151.2 (s), 154.5 (s), 154.7 (s), 168.1 (s), 168.4 (s), 168.6 (s), 169.5 (s), 169.7 (s); exact mass (electrospray) m/z calcd for $C_{14}H_{19}N_{2}O_{5}$ (M + H) 295.1288, found, 295.1290.

Methyl 1,4-Dimethyl-3,6-dioxopiperazine-2-carboxylate (12c).¹³ NaH (60% w/w dispersion in mineral oil, 35 mg, 0.865 mmol) was added in one portion to a stirred solution of 12b (124 mg, 0.422 mmol) in dry THF (21 mL) containing *t*-BuOH (8.3 μL, 0.0865 mmol). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 24 h. The mixture was cooled (ice bath) and glacial AcOH (50 μL, 0.865 mmol) was added and the solvent was evaporated. Flash chromatography of the residue over silica gel (2 x 8 cm), using 80% to 100% EtOAc in hexanes, gave $12c^{13}$ (47 mg, 55%) as a white solid: mp 121-123 °C; FTIR (CH₂Cl₂, cast) 2952, 1740, 1676, 1485, 1405, 1236 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 2.94 (s, 3 H), 2.99 (s, 3 H), 3.83 (s, 3 H), 3.84 (d, J = 17.5 Hz, 1 H), 4.17 (d, J = 17.5 Hz, 1 H), 4.58 (s, 1 H); ¹³C NMR (DMSO- d_6 , 125 MHz) δ 33.0 (q), 34.0 (q), 51.8 (t), 53.7 (q), 66.0 (d), 160.2 (s), 164.7 (s), 167.0 (s); exact mass (electrospray) m/z calcd for C₈H₁₂N₂NaO₄ (M + Na) 223.0689, found, 223.0685. Crystals for X-ray analysis were grown from EtOAc-hexanes, as described in the General Procedures section.

3-Benzoyl-1-benzyl-4-[(4-methoxyphenyl)methyl]-6-methylpiperazine-2,5-dione (9i). NaH (60% w/w dispersion in mineral oil, 30 mg, 0.745 mmol) was added in one portion to a stirred solution of 9g (195 mg, 0.363 mmol) in dry THF (18 mL). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 2.5 h. The mixture was cooled (ice bath) and pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 8 cm), using 30% to 60% EtOAc in hexanes, gave 9i (69 mg,

74%) as a white foam: $[\alpha]_D^{20}$ -72.02 (*c* 1.10, CH₂Cl₂); FTIR (neat, film) 3064, 3031, 2997, 2939, 2837, 1692, 1667, 1513, 1450, 1305, 1247, 1172 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 1.58 (d, *J* = 7.0 Hz, 3 H), 3.74 (m, 3 H), 3.87 (d, *J* = 15.0 Hz, 1 H), 3.91 (d, *J* = 15.0 Hz, 1 H), 4.06 (q, *J* = 7.0 Hz, 1 H), 5.03 (d, *J* = 15.0 Hz, 1 H), 5.13 (d, *J* = 15.0 Hz, 1 H), 5.65 (s, 1 H), 6.72-6.75 (m, part of AA'BB' spin system, 2 H), 7.00-7.03 (m, part of AA'BB' spin system, 2 H), 7.18-7.33 (m, 5 H), 7.46 (t, *J* = 8.0 Hz, 2 H), 7.61 (t, *J* = 7.5 Hz, 1 H), 8.04-8.06 (m, 2 H); ¹³C NMR (DMSO-*d*₆, 125 MHz) δ 18.5 (q), 47.3 (t), 48.2 (t), 55.3 (q), 55.7 (d), 64.3 (d), 114.2 (d), 114.3 (d), 126.3 (s), 128.1 (d), 128.1 (d), 128.6 (d), 128.7 (d), 128.8 (d), 128.9 (d), 129.9 (d), 130.5 (d), 130.6 (d), 134.3 (s), 134.4 (d), 135.3 (s), 159.6 (s), 160.6 (s), 168.6 (s), 192.6 (s); exact mass (electrospray) *m*/*z* calcd for C₂₇H₂₇N₂O₄ (M + H) 443.1965, found, 443.1964.

Phenyl *N*-({Benzyl([2-(4-methoxyphenyl)-2-oxoethyl]carbamoyl}methyl)-*N*-methyl-carbamate (13c). Dess-Martin periodinane (397 mg, 0.938 mmol) was added to a stirred solution of 13b (280 mg, 0.626 mmol), in dry CH₂Cl₂ (13 mL), and stirring was continued for 5 h. Et₂O was added and the solution was stirred until cloudy. Aqueous NaOH (2 M) was added and the mixture was stirred until the phases became clear. The aqueous phase was extracted with Et₂O and the combined organic extracts were dried (MgSO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 8 cm), using 40% to 60% EtOAc in hexanes, gave 13c [183 mg, 66% or 92% after correction for recovered 13b (79 mg)] as a white foam: FTIR (CHCl₃, cast) 3008, 2935, 2838, 1726, 1663, 1514, 1397, 1248, 1205 cm⁻¹; ¹H NMR (DMSO- d_6 , 400 MHz) δ 2.88-3.03 (four s, 3 H), 3.82-3.83 (m, 3 H), 4.07-4.39 (four s, 2 H), 4.53-4.65 (two m, 2 H), 4.76-4.95 (m, 2 H), 7.01-7.07 (m, 3.5 H), 7.18-7.39 (m, 9 H), 7.93-7.97 (m, 1.5 H); ¹³C NMR (DMSO- d_6 , 125 MHz) δ 36.0 (q), 36.2 (q), 36.6 (q), 36.7 (q), 50.7 (t), 50.8 (t), 51.0 (t), 51.1 (t), 51.2 (t), 53.2 (t), 53.4 (t), 56.0 (q), 56.1 (q), 114.4 (d), 122.1 (d), 122.2 (d),

125.5 (d), 125.6 (d), 125.7 (d), 127.4-130.9 (numerous d and one s), 137.4 (s), 137.4 (s), 138.0 (s), 138.0 (s), 151.7 (s), 151.7 (s), 151.7 (s), 151.8 (s), 155.0 (s), 155.0 (s), 155.1 (s), 155.3 (s), 163.8 (s), 164.1 (s), 168.7 (s), 169.1 (s), 169.1 (s), 169.6 (s), 192.8 (s), 193.4 (s), 193.4 (s); exact mass (electrospray) m/z calcd for $C_{26}H_{26}N_2NaO_5$ (M + Na) 469.1734, found, 469.1727.

4-Benzyl-3-[(4-Methoxyphenyl)carbonyl]-1-methylpiperazine-2,5-dione (13d). NaH (60% w/w dispersion in mineral oil, 22 mg, 0.545 mmol) was added in one portion to a stirred solution of 13c (118 mg, 0.266 mmol) in dry THF (13.3 mL). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 30 min. The mixture was cooled (ice bath) and pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 10 cm), using 40% to 50% EtOAc in hexanes, gave 13d [50 mg, 54%] or 70% after correction for recovered 13c (27 mg)] as pale yellow crystals: mp 139-140 °C, FTIR (CHCl₃, cast) 3333, 3065, 3010, 2936, 2842, 1672, 1598, 1453, 1251, 1170 cm⁻¹; ¹H NMR $(CDCl_3, 300 \text{ MHz}) \delta 2.91 \text{ (s, 3 H)}, 3.83-3.93 \text{ (m, 5 H)}, 4.34 \text{ (d, } J = 17.1 \text{ Hz, 1 H)}, 5.14 \text{ (d, } J$ 14.7 Hz, 1 H), 5.46 (s, 1 H), 6.90-6.93 (m, part of AA'BB' spin system, 2 H), 7.13-7.16 (m, 2 H), 7.23-7.26 (m, 3 H), 8.00-8.03 (m, part of AA'BB' spin system, 2 H); ¹³C NMR (CDCl₃, 125 MHz) δ 33.9 (g), 48.6 (t), 52.4 (t), 64.7 (g), 114.0 (d), 127.0 (d), 128.2 (s), 128.8 (d), 129.0 (d), 132.4 (d), 134.7 (s), 160.9 (s), 164.8 (s), 166.1 (s), 190.4(s); exact mass (electrospray) m/z calcd for $C_{20}H_{21}N_2O_4$ (M + H) 353.1496, found, 353.1492.

Phenyl N-({Benzyl[(diethoxyphosphoryl)methyl]carbamoyl}methyl)-N-methyl-carbamate (14b). NaHCO₃ (267 mg, 3.18 mmol) was added to a stirred and cooled (0 °C) solution of 14a⁶ (328 mg, 1.27 mmol) in dioxane (4.5 mL) and water (4.5 mL). Acid chloride 7¹ (363 mg, 1.59 mmol) in dry THF (2 mL) was added dropwise over 15 min. The cooling bath

was left in place, but not recharged, and stirring was continued overnight. The THF and dioxane were evaporated and the aqueous solution was extracted with CH_2Cl_2 . The combined organic extracts were dried (Na_2SO_4) and evaporated. Flash chromatography of the residue over silica gel (2 x 12 cm), using 70% to 100% EtOAc in hexanes, gave **14b** (448 mg, 84%) as a colorless oil: FTIR (CH_2Cl_2 , cast) 3064, 3031, 2983, 2933, 1730, 1668, 1453, 1395, 1242, 1206, 1050, 1025 cm⁻¹; ^{1}H NMR ($DMSO-d_6$, 400 MHz) δ 1.15-1.25 (m, 6 H), 2.89-3.05 (four s, 3 H), 3.72-3.81 (m, 2 H), 3.98-4.09 (m, 4 H), 4.25-4.54 (four s, 2 H), 4.67-4.73 (m, 2 H), 7.00-7.04 (m, 1.2 H), 7.08-7.13 (m, 0.8 H), 7.18-7.40 (m, 8 H); ^{13}C NMR ($DMSO-d_6$, 100 MHz) δ 16.1 (q), 16.1 (q), 16.2 (q), 35.7 (q), 35.7 (q), 36.0 (q), 36.1 (q), 41.0 (t), 42.5 (t), 49.2 (t), 49.5 (t), 49.9 (t), 50.4 (t), 50.5 (t), 50.6 (t), 50.7 (t), 61.7 (t), 61.8 (t), 62.0 (t), 62.1 (t), 121.5 (d), 121.6 (d), 125.0 (d), 125.1 (d), 126.5 (d), 126.7 (d), 127.2 (d), 127.5 (d), 128.4 (d), 128.7 (d), 128.8 (d), 129.1 (d), 129.2 (d), 136.0 (s), 136.6 (s), 151.1 (s), 151.2 (s), 151.3 (s), 154.5 (s), 154.6 (s), 154.8 (s), 167.9 (s), 168.0 (s), 168.3 (s), 168.5 (s); exact mass (electrospray) m/z calcd for $C_{22}H_{29}N_2NaO_6P$ (M + Na) 471.1655, found, 471.1648.

Diethyl (1-Benzyl-4-methyl-3,6-dioxopiperazin-2-yl)phosphonate (14c). NaH (60% w/w dispersion in mineral oil, 67 mg, 1.67 mmol) was added in one portion to a stirred solution of 14b (340 mg, 0.812 mmol) and *t*-BuOH (16 μL, 0.166 mmol) in dry THF (40 mL). The reaction flask was lowered into a preheated oil bath (70 °C) and the mixture was stirred for 4.5 h. The mixture was cooled (ice bath) and pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 10 cm), using 0% to 6% MeOH in EtOAc, gave 14c (126 mg, 44%) as a colorless oil: FTIR (CDCl₃, cast) 2982, 2934, 1678, 1452, 1254, 1046, 1017 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) (the spectrum showed the presence of a

byproduct, see text) δ 1.28-1.41 (m, 6 H), 2.99 (m, 3 H), 3.84 (dd, J = 1.5, 18.0 Hz, 1 H), 4.07 (d, J = 12 Hz, 1 H), 4.14-4.27 (m, 5 H), 4.43 (dd, J = 5.0, 18.0 Hz, 1 H), 5.58 (d, J = 14.7 Hz, 1 H), 7.21-7.36 (m, 5 H); ¹³C NMR (CDCl₃, 125 MHz) δ 16.4 (q), 16.5 (q), 16.5 (q), 16.5 (q) (the last four signals represent coupling of two diastereotopic CH₃ groups to ³¹P), 34.1 (q), 48.1 (t), 52.4 (t), 57.3 (d), 58.4 (d) (the last two signals represent coupling of the CH signal to ³¹P), 63.6 (t), 63.7 (t), 64.1 (t), 64.2 (t) (the last four signals represent coupling of two diastereotopic CH₂ groups to ³¹P), 128.3 (d), 128.5 (d), 129.1 (d), 134.8 (s), 161.3 (s), 164.6 (s); exact mass (electrospray) m/z calcd for C₁₆H₂₃N₂NaO₅P (M + Na) 377.1237, found, 377.1233.

(3E)-4-Benzyl-3-1(4-methoxyphenyl)methylidenel-1-methylpiperazine-2.5-dione (14d) and (3E)-1-Benzyl-3-[(4-methoxyphenyl)methylidene]-4-methylpiperazine-2,5-dione (14d'). A solution of 14c (93 mg, 0.262 mmol) and p-anisaldehyde (35 µL, 0.289 mmol) in dry THF (9.6 mL) was added to a stirred and cooled (0 °C) mixture of NaH (60% w/w dispersion in mineral oil, 15 mg, 0.385 mmol) in dry THF (5.8 mL). The mixture was stirred for 2 h at 0 °C and then at room temperature for 1 h. Saturated agueous NH₄Cl (1.7 mL) and water (1.7 mL) were added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 10 cm), using 30% to 80% EtOAc in hexanes, gave 14d (44 mg, 50%) as a colorless oil and 14d' (13 mg, 15 %) as a yellow oil. Compound **14d** had: FTIR (CDCl₃, cast) 3317, 3063, 3007, 2933, 2837, 1679, 1606, 1512, 1398, 1251 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 3.05 (s, 3 H), 3.77 (s, 3 H), 4.19 (s, 2 H), 5.06 (s, 2 H), 6.49 (s, 1 H), 6.79-6.80 (m, 2 H), 7.26-7.29 (m, 5 H), 7.32-7.36 (m, 2 H); ¹³C NMR (CDCl₃, 125 MHz) δ 33.9 (q), 48.1 (t), 52.2 (t), 55.2 (q), 113.2 (d), 124.8 (d), 126.3 (s), 126.8 (d), 127.5 (d), 128.5 (s), 128.9 (d), 131.2 (d), 135.9 (s), 159.4 (s), 160.0 (s), 163.9 (s); exact mass (electrospray) m/z calcd for $C_{20}H_{20}N_2NaO_3$ (M + Na) 359.1366,

found, 359.1366. Compound **14d'** had: FTIR (CHCl₃, cast) 3335, 3007, 2933, 2837, 1680, 1607, 1512, 1252, 1178 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 3.29 (s, 3 H), 3.83 (s, 3 H), 3.97 (s, 2 H), 4.65 (s, 2 H), 6.49 (s, 1 H), 6.88-6.90 (m, 2 H), 7.26-7.35 (m, 5 H), 7.46-7.48 (m, 2 H); ¹³C NMR (CDCl₃, 125 MHz) δ 31.0 (q), 49.4 (t), 49.5 (t), 55.3 (q), 113.4 (d), 123.7 (d), 126.4 (s), 128.1 (d), 128.4 (d), 129.0 (d), 129.6 (s), 131.4 (d), 135.4 (s), 159.5 (s), 159.8 (s), 163.9 (s); exact mass (electrospray) m/z calcd for $C_{20}H_{21}N_2O_3$ (M + H) 337.1547, found, 337.1546.

3-Benzyl-1-methylimidazolidine-2,4-dione (6h).⁸ O₂ was bubbled for 4 min into a stirred solution of **6d** (202 mg, 0.485 mmol) in dry THF (24 mL). NaH (60% w/w dispersion in mineral oil, 40 mg, 0.994 mmol) was added in one portion and the reaction flask was lowered into a preheated oil bath (70 °C). The mixture was stirred for 2.5 h under O₂ (balloon). The mixture was cooled (ice bath) and pH 7 buffer was added. The aqueous solution was extracted with EtOAc and the combined organic extracts were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (2 x 10 cm), using 30% to 60% EtOAc in hexanes, gave **6h** (55 mg, 56%) as a white foam: FTIR (CHCl₃, cast) 3033, 2918, 1773, 1712, 1485, 1451, 1411 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 2.99 (s, 3 H), 3.86 (s, 2 H), 4.65 (s, 2 H), 7.29-7.43 (m, 5 H); ¹³C NMR (CDCl₃, 125 MHz) δ 29.7 (q), 42.6 (t), 51.8 (t), 128.0 (d), 128.7 (d), 128.8 (d), 136.1 (s), 156.6 (s), 169.5 (s); exact mass (electrospray) *m/z* calcd for C₁₁H₁₂N₂O₂ (M + H) 205.0972, found, 205.0969.

ACKNOWLEDGMENTS

We thank NSERC for financial support. C.L.A. holds a Queen Elizabeth II Graduate Scholarship.

Supporting Information Available: X-ray data (cif and ORTEP diagrams) for compounds **10d**, **11c** and **12c**, experimental procedures, and copies of NMR spectra. This material is available free of charge via the Internet at http://pubs.acs.org.

REFERENCES

- (1) Peng, J.; Clive, D. L. J. J. Org. Chem. 2009, 74, 513-519.
- (2) (a) Rajappa, S.; Natekar, M. V. Adv. Heterocycl. Chem. 1993, 57, 187-289. (b) Sammes,
 P. G. Fortschr. Chem. Org. Naturst. 1975, 32, 51-118. (c) Dinsmore, C. J.; Beshore, D. C. Tetrahedron 2002, 58, 3297-3312. (d) Martins, M. B.; Carvalho, I. Tetrahedron 2007, 63, 9923-9932.
- (3) E.g. (a) Rameshkumar, N.; Ashokkumar, M.; Subramanian, E. H.; Ilavarasan, R.; Sridhar, S. K. Eur. J. Med. Chem. 2003, 38, 1001-1114. (b) McCleland, K.; Milne, P. J.; Lucieto, F. R.; Frost, C.; Brauns, S. C.; van De Venter, Du Plessis, J.; Dyason, K.; J. Pharm. Pharmacol. 2004, 56, 1143-1153. (c) Kanoh, K.; Kohno, S.; Asari, T.; Harada, T.; Katada, J.; Muramatsu, M.; Kawashima, H.; Sekiya, H.; Uno, I. Bioorg. Med. Chem. Lett. 1997, 7, 2847-2852.
- (4) (a) Horton, D. A.; Bourne, G. T.; Smythe, M. L. *Mol. Diversity* **2000**, *5*, 289-304 and references therein. (b) Nadin, A.; Hattotuwagama, C.; Churcher, I. *Angew. Chem. Int. Ed.* **2012**, *51*, 1114-1122.
- (5) Recent examples of other routes to unsymmetrical piperazine-2,5-diones: (a) Tullberg, M.; Grøtli, M.; Luthmn, K. *J. Org. Chem.* **2007**, *72*, 195-199. (b) Davies, S. G.; Garner, A. C.; Ouzman, J. V. A.; Roberts, P. M.; Smith, A. D.; Snow, E. J.; Thomson, J. E.; Tamayo, J. A.; Vickers, R. J. *Org. Biomol. Chem.* **2007**, *5*, 2138-2147. (c) Chai, C. L. L.; Elix, J. A.; Huleatt, P. B. *Tetrahedron* **2005**, *61*, 8722-8739. (d) Long, D. D.; Tennant-Eyles, R. J.; Estevez, J. C.;

Wormald, M. R.; Dwek, R. A.; Smith, M. D.; Fleet, G. W. J. J. Chem. Soc., Perkin Trans. 1 2001, 807-813.

- (6) Lewis, R. T.; Motherwell, W. B. *Tetrahedron* **1992**, *48*, 1465-1484.
- (7) (a) Overman, L. E.; Rosen, M. D. *Tetrahedron* 2010, 66, 6514-6525. (b) Davies, S. G.; Rodríguez-Solla, H.; Tamayo, J. A.; Cowley, A. R.; Concellón, C.; Garner, A. C.; Parkes, A. L.; Smith, A. D. *Org. Biomol. Chem.* 2005, 3, 1435-1447. (c) Du, Y.; Wiemer, D. F. *J. Org. Chem.* 2002, 67, 5709-5717. (d) Overman, L. E.; Rosen, M. D. *Angew. Chem. Int. Ed.* 2000, 39, 4596-4599. (e) Alcaraz, C.; Herrero, A.; Marco, J. L.; Fernández-Alvarez, E.; Bernabé, M. *Tetrahedron Lett.* 1992, 33, 5605-5608. (f) Lieberknecht, A.; Griesser, H. *Tetrahedron Lett.* 1987, 28, 4425-4278.
 - (8) Hoffman, R. V.; Reddy, M. M.; Cervantes-Lee, F. J. Org. Chem. 2000, 65, 2591-2595.
 - (9) Watson, I. D. G.; Yudin, A. K. J. Org. Chem. 2003, 68, 5160-5167.
- (10) Polaske, N. W.; Dubey, R.; Nichol, G. S.; Olenyuk, B. *Tetrahedron: Asymmetry* **2009**, 20, 2742-2750. Our ¹H NMR spectrum of **8d** differs from the reported data.
 - (11) Broggini, G.; Garanti, L.; Molteni, G.; Zecchi, G. Tetrahedron 1998, 54, 14859-14868.
- (12) Arshady, R.; Atherton, E.; Clive, D. L. J.; Sheppard, R. C. J. Chem. Soc., Perkin Trans. 1 1981, 529-537.
- (13) Polaske, N. W.; Nichol, G. S.; Szabó, L. Z.; Olenyuk, B. Crystal Growth & Design 2009, 9, 2191-2197.